Biomica is a clinical-stage biopharmaceutical company dedicated to developing innovative microbiome-based therapeutics for the treatment of cancer, immune-mediated, and infectious diseases. Synergizing proprietary big data and computational capabilities, Biomica develops best-in-class therapeutics to address high-value, unmet medical needs.
Our unique approach is focused on understanding the functional elements of the microbiome. This enables us to select a minimal number of desired microbial candidates, thereby maximizing beneficial effects while minimizing potential adverse effects through carefully curated consortia.
Our drug candidates have been identified and designed using PRISM, a proprietary cutting-edge computational platform that integrates advanced AI capabilities, ‘Big Data’, and a comprehensive proprietary database. Through metagenomics sequencing, Biomica gains deeper insights into the microbiome, employing high-resolution taxonomy and functional profiling of the human microbiome. These insights enable us to develop novel solutions for complex host-microbiome interrelations and make clinically relevant predictions.
Preliminary Phase 1 results show promising trends for BMC128 in combination with nivolumab in refractory cancer patients. Data will be showcased at the 2024 American Society of Clinical Oncology (ASCO) annual meeting REHOVOT, Israel, May 23, 2024. Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: […]
